Detail

Paliperidone

Description

Name: Paliperidone
Type: small molecule
Groups: approved
Indication: For the treatment of schizophrenia.
Accession Number: DB01267 ( DB01267)
Description: Paliperidone is the primary active metabolite of the older antipsychotic risperidone. While its specific mechanism of action is unknown, it is believed that paliperidone and risperidone act via similar if not the same pathways. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006.
Structure:
Prescription Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
Invegatablet, extended release6 mg/1oral19-12-2006US
Invegatablet, extended release3 mg/1oral27-03-2013US
Invegatablet (extended-release)12 mgoral01-01-1970Canada
Invegatablet, extended release3 mg/1oral19-12-2006US
Invegatablet, extended release6 mg/1oral19-12-2006US
Invegatablet, extended release9 mg/1oral19-12-2006US
Invegatablet, extended release1.5 mg/1oral10-09-2009US
Invegatablet, extended release3 mg/1oral19-12-2006US
Invegatablet (extended-release)3 mgoral02-10-2007Canada
Invegatablet (extended-release)6 mgoral02-10-2007Canada
Invegatablet (extended-release)9 mgoral02-10-2007Canada
Invega Sustennasuspension (extended-release)50 mgintramuscular21-07-2010Canada
Invega Sustennasuspension (extended-release)75 mgintramuscular21-07-2010Canada
Invega Sustennasuspension (extended-release)100 mgintramuscular21-07-2010Canada
Invega Sustennasuspension (extended-release)150 mgintramuscular21-07-2010Canada
Invega Sustennainjection39 mg/.25mLintramuscular31-07-2009US
Invega Sustennainjection78 mg/.5mLintramuscular31-07-2009US
Invega Sustennainjection117 mg/.75mLintramuscular31-07-2009US
Invega Sustennainjection156 mg/mLintramuscular31-07-2009US
Invega Sustennainjection234 mg/1.5mLintramuscular31-07-2009US
Invega Sustennasuspension (extended-release)25 mgintramuscular01-01-1970Canada
Invega Trinzainjection, suspension, extended release273 mg/.875mLintramuscular19-05-2015US
Invega Trinzainjection, suspension, extended release410 mg/1.315mLintramuscular19-05-2015US
Invega Trinzainjection, suspension, extended release546 mg/1.75mLintramuscular19-05-2015US
Invega Trinzainjection, suspension, extended release819 mg/2.625mLintramuscular19-05-2015US
Paliperidonetablet, extended release1.5 mg/1oral29-09-2015US
Paliperidonetablet, extended release3 mg/1oral01-03-2015US
Paliperidonetablet, extended release1.5 mg/1oral24-09-2015US
Paliperidonetablet, extended release3 mg/1oral24-09-2015US
Paliperidonetablet, extended release6 mg/1oral24-09-2015US
Paliperidonetablet, extended release9 mg/1oral24-09-2015US

Generic Prescription Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
Paliperidonetablet, film coated, extended release1.5 mg/1oral24-09-2015US
Paliperidonetablet, film coated, extended release3 mg/1oral24-09-2015US
Paliperidonetablet, film coated, extended release6 mg/1oral24-09-2015US
Paliperidonetablet, film coated, extended release9 mg/1oral24-09-2015US
Paliperidonetablet, film coated, extended release1.5 mg/1oral24-09-2015US
Paliperidonetablet, film coated, extended release3 mg/1oral24-09-2015US
Paliperidonetablet, film coated, extended release6 mg/1oral24-09-2015US
Paliperidonetablet, film coated, extended release9 mg/1oral24-09-2015US

Over the Counter Products: Not Available
International Brands
  • No Brands

Brand Names
  • No Brands

Brand Mixtures
Brand NameIngredients
PaliperidonePaliperidone
PaliperidonePaliperidone
PaliperidonePaliperidone
PaliperidonePaliperidone
PaliperidonePaliperidone
PaliperidonePaliperidone
PaliperidonePaliperidone
PaliperidonePaliperidone
PaliperidonePaliperidone
PaliperidonePaliperidone
PaliperidonePaliperidone
PaliperidonePaliperidone
InvegaPaliperidone
InvegaPaliperidone
InvegaPaliperidone
InvegaPaliperidone
InvegaPaliperidone
Invega SustennaPaliperidone
Invega SustennaPaliperidone
Invega SustennaPaliperidone
Invega SustennaPaliperidone
Invega SustennaPaliperidone
Invega TrinzaPaliperidone
Invega TrinzaPaliperidone
Invega TrinzaPaliperidone
Invega TrinzaPaliperidone
InvegaPaliperidone
InvegaPaliperidone
PaliperidonePaliperidone
PaliperidonePaliperidone
InvegaPaliperidone
InvegaPaliperidone
InvegaPaliperidone
Invega SustennaPaliperidone
Invega SustennaPaliperidone
Invega SustennaPaliperidone
Invega SustennaPaliperidone
InvegaPaliperidone
Invega SustennaPaliperidone

Categories
  • Antipsychotic Agents

Pharmacology

Indication: For the treatment of schizophrenia.
Pharmacodynamics: Not Available
Mechanism of action: Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone, as with other drugs having efficacy in schizophrenia, is unknown, but it has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism.
Absorption: The absolute oral bioavailability of paliperidone following paliperidone administration is 28%.
Volume of distribution:
  • 487 L

Protein binding: The plasma protein binding of racemic paliperidone is 74%.
Metabolism: Not Available
Route of elimination: One week following administration of a single oral dose of 1 mg immediate-release 14C-paliperidone to 5 healthy volunteers, 59% (range 51% – 67%) of the dose was excreted unchanged into urine, 32% (26% – 41%) of the dose was recovered as metabolites, and 6% – 12% of the dose was not recovered.
Half life: The terminal elimination half-life of paliperidone is approximately 23 hours.
Clearance: Not Available
Toxicity: The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.
Affected organisms
  • Not Available

SNP Mediated Adverse Drug Reactions
  • Not Available

Pharmacoeconomics

Manufacturers:
  • Not Available

Packagers:
Dosage forms
FormRouteStrength
Tablet (extended-release)oral12 mg
Tablet (extended-release)oral3 mg
Tablet (extended-release)oral6 mg
Tablet (extended-release)oral9 mg
Injectionintramuscular117 mg/.75mL
Injectionintramuscular156 mg/mL
Injectionintramuscular234 mg/1.5mL
Injectionintramuscular39 mg/.25mL
Injectionintramuscular78 mg/.5mL
Suspension (extended-release)intramuscular100 mg
Suspension (extended-release)intramuscular150 mg
Suspension (extended-release)intramuscular25 mg
Suspension (extended-release)intramuscular50 mg
Suspension (extended-release)intramuscular75 mg
Injection, suspension, extended releaseintramuscular273 mg/.875mL
Injection, suspension, extended releaseintramuscular410 mg/1.315mL
Injection, suspension, extended releaseintramuscular546 mg/1.75mL
Injection, suspension, extended releaseintramuscular819 mg/2.625mL
Tablet, extended releaseoral1.5 mg/1
Tablet, extended releaseoral3 mg/1
Tablet, extended releaseoral6 mg/1
Tablet, extended releaseoral9 mg/1
Tablet, film coated, extended releaseoral1.5 mg/1
Tablet, film coated, extended releaseoral3 mg/1
Tablet, film coated, extended releaseoral6 mg/1
Tablet, film coated, extended releaseoral9 mg/1

Prices
Unit descriptionCostUnit
Invega er 1.5 mg tablet$15.72tablet
Invega er 3 mg tablet$23.09tablet
Invega er 9 mg tablet$23.59tablet
Invega er 6 mg tablet$28.62tablet
Invega sustenna 39 mg pref syringe$296.45syringe

Patents
CountryPatent NumberApprovedExpires (estimated)
2000786Canada1999-01-262009-10-16
2494234Canada2009-10-272023-07-28
5254556United States1993-10-272010-10-27
6555544United States1998-11-102018-11-10

Interactions

Drug Interactions
DrugInteraction
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Paliperidone.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Paliperidone.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Paliperidone.
AmisulprideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Paliperidone.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Paliperidone.
AmphetaminePaliperidone may decrease the stimulatory activities of Amphetamine.
AzelastinePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Paliperidone.
BenzphetaminePaliperidone may decrease the stimulatory activities of Benzphetamine.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Paliperidone.
BuprenorphinePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Paliperidone.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Paliperidone.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Paliperidone.
CarbamazepineThe serum concentration of Paliperidone can be decreased when it is combined with Carbamazepine.
CathinonePaliperidone may decrease the stimulatory activities of Cathinone.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Paliperidone.
CitalopramCitalopram may increase the QTc-prolonging activities of Paliperidone.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Paliperidone.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Paliperidone.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Paliperidone.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Paliperidone.
DextroamphetaminePaliperidone may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Paliperidone.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Paliperidone.
DofetilideDofetilide may increase the QTc-prolonging activities of Paliperidone.
DonepezilDonepezil may increase the central neurotoxic activities of Paliperidone.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Paliperidone.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Paliperidone.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Paliperidone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Paliperidone.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Paliperidone.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Paliperidone.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Paliperidone.
EthanolPaliperidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Paliperidone.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Paliperidone.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Paliperidone.
FosphenytoinThe serum concentration of Paliperidone can be decreased when it is combined with Fosphenytoin.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Paliperidone.
GalantamineGalantamine may increase the central neurotoxic activities of Paliperidone.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Paliperidone.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Paliperidone.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Paliperidone.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Paliperidone.
GoserelinGoserelin may increase the QTc-prolonging activities of Paliperidone.
HydrocodonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Paliperidone.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Paliperidone.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Paliperidone.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Paliperidone.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Paliperidone.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Paliperidone.
Insulin RegularThe therapeutic efficacy of Insulin Regular can be decreased when used in combination with Paliperidone.
Insulin, isophaneThe therapeutic efficacy of Insulin, isophane can be decreased when used in combination with Paliperidone.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Paliperidone.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Paliperidone.
IvabradineIvabradine may increase the QTc-prolonging activities of Paliperidone.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Paliperidone.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Paliperidone.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Paliperidone.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Paliperidone.
LisdexamfetaminePaliperidone may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Paliperidone.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Paliperidone.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Paliperidone.
LumacaftorThe serum concentration of Paliperidone can be decreased when it is combined with Lumacaftor.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Paliperidone.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Paliperidone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Paliperidone.
MethamphetaminePaliperidone may decrease the stimulatory activities of Methamphetamine.
MethotrimeprazinePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethylphenidateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methylphenidate.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Paliperidone.
MetyrosinePaliperidone may increase the sedative activities of Metyrosine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Paliperidone.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Paliperidone.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Paliperidone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Paliperidone.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Paliperidone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Paliperidone.
OctreotideOctreotide may increase the QTc-prolonging activities of Paliperidone.
OrphenadrinePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ParaldehydePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Paroxetine.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Paliperidone.
PhendimetrazinePaliperidone may decrease the stimulatory activities of Phendimetrazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Paliperidone.
PhenobarbitalThe serum concentration of Paliperidone can be decreased when it is combined with Phenobarbital.
PhenterminePaliperidone may decrease the stimulatory activities of Phentermine.
PhenytoinThe serum concentration of Paliperidone can be decreased when it is combined with Phenytoin.
PrimidoneThe serum concentration of Paliperidone can be decreased when it is combined with Primidone.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Paliperidone.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Paliperidone.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Paliperidone.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Paliperidone.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Paliperidone.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Paliperidone.
RifampicinThe serum concentration of Paliperidone can be decreased when it is combined with Rifampicin.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Paliperidone.
RivastigmineRivastigmine may increase the central neurotoxic activities of Paliperidone.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Paliperidone.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Paliperidone.
SaquinavirThe serum concentration of Paliperidone can be increased when it is combined with Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Paliperidone.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Paliperidone.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Paliperidone.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
St. John's WortThe serum concentration of Paliperidone can be decreased when it is combined with St. John's Wort.
SulpirideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Paliperidone.
SuvorexantPaliperidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TacrineTacrine may increase the central neurotoxic activities of Paliperidone.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Paliperidone.
TesmilifeneThe serum concentration of Paliperidone can be decreased when it is combined with Tesmilifene.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Paliperidone.
ThalidomidePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Paliperidone.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Paliperidone.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Paliperidone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Paliperidone.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Paliperidone.
Valproic AcidThe serum concentration of Paliperidone can be increased when it is combined with Valproic Acid.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Paliperidone.
VerapamilThe serum concentration of Paliperidone can be increased when it is combined with Verapamil.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Paliperidone.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Paliperidone.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Paliperidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Paliperidone.
ZolpidemPaliperidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Food Interactions:
  • Avoid alcohol.

Taxonomy

Kingdom: Organic compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
  • Aralkylamines
  • Aryl fluorides
  • Azacyclic compounds
  • Benzisoxazoles
  • Fluorobenzenes
  • Heteroaromatic compounds
  • Hydrocarbon derivatives
  • Isoxazoles
  • Lactams
  • Organofluorides
  • Oxacyclic compounds
  • Oxazoles
  • Piperidines
  • Pyridines and derivatives
  • Pyrimidones
  • Secondary alcohols
  • Trialkylamines

substituent:
  • Alcohol
  • Amine
  • Aralkylamine
  • Aromatic heteropolycyclic compound
  • Aryl fluoride
  • Aryl halide
  • Azacycle
  • Azole
  • Benzenoid
  • Benzisoxazole
  • Fluorobenzene
  • Heteroaromatic compound
  • Hydrocarbon derivative
  • Isoxazole
  • Lactam
  • Organofluoride
  • Organohalogen compound
  • Organonitrogen compound
  • Organooxygen compound
  • Oxacycle
  • Oxazole
  • Piperidine
  • Pyridine
  • Pyridopyrimidine
  • Pyrimidine
  • Pyrimidone
  • Secondary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine

References

Synthesis Reference: Santiago Ini, Naama Chasid, Kobi Chen, Osnat Porter-Kleks, "Pure paliperidone and processes for preparing thereof." U.S. Patent US20080171876, issued July 17, 2008.
General Reference: # Jones MP, Nicholl D, Trakas K: Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia. Int J Clin Pharmacol Ther. 2010 Jun;48(6):383-99. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20497747 # Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18537577
External Links:
ResourceLink
RxListhttp://www.rxlist.com/cgi/generic/invega.htm
PDRhealthhttp://www.pdrhealth.com/drugs/rx/rx-mono.aspx?contentFileName=inv1883.html&contentName=Invega&contentId=405
Drugs.comhttp://www.drugs.com/cdi/paliperidone.html

ATC Codes:
  • Array

AHFS Codes:
  • 28:16.08.04

MSDS: Download
SiteLock

© Copyright 2022 The Purple Society, Purple Gladiator, Trialsmap, The Purple Drug Guide, and One Person CAN Make A Difference! are all registered trademarks of The Purple Society. The Purple Society, a not-for-profit, section 501(c)(3) #273785281.

The Purple Society website is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.

CONTACT US

The Purple Society team is here for you 24 hours a day, 7 days a week. Send us an email and we'll get right back to you.

Sending
or

Log in with your credentials

Forgot your details?